Skip to main content

Advertisement

SpringerLink
Log in

Construction and Analysis of a Mitochondrial Metabolism-Related Prognostic Model for Breast Cancer to Evaluate Survival and Immunotherapy

  • Published:
The Journal of Membrane Biology Aims and scope Submit manuscript

Abstract

As one of the most prevalent malignancies among women, breast cancer (BC) is tightly linked to metabolic dysfunction. However, the correlation between mitochondrial metabolism-related genes (MMRGs) and BC remains unclear. The training and validation datasets for BC were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases, respectively. MMRG-related data were obtained from the Molecular Signatures Database. A risk score prognostic model incorporating MMRGs was established based on univariate, LASSO, and multivariate Cox regression analyses. Independent factors affecting BC prognosis were identified through regression analysis and presented in a nomogram. Single-sample gene set enrichment analysis was employed to assess the immune levels of high-risk (HR) and low-risk (LR) groups. The sensitivity of BC patients in the two groups to common anti-tumor drugs was evaluated by utilizing the Genomics of Drug Sensitivity in Cancer database. 12 MMRGs significantly associated with survival were selected from 1234 MMRGs. A 12-gene risk score prognostic model was built. In the multivariate regression analysis incorporating classical clinical factors, the MMRG-related risk score remained an independent prognostic factor. As revealed by tumor immune microenvironment analysis, the LR group with higher survival rates had elevated immune levels. The drug sensitivity results unmasked that the LR group demonstrated higher sensitivity to Irinotecan, Nilotinib, and Oxaliplatin, while the HR group demonstrated higher sensitivity to Lapatinib. The development of MMRG characteristics provides a comprehensive understanding of mitochondrial metabolism in BC, aiding in the prediction of prognosis and tumor microenvironment, and offering promising therapeutic choices for BC patients with different MMRG risk scores.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

Data Availability

The data and materials in the current study are available from the corresponding author on reasonable request.

References

  • Agarwal S et al (2020) PAICS, a De Novo purine biosynthetic enzyme, is overexpressed in pancreatic cancer and is involved in its progression. Transl Oncol 13(7):100776

    Article  PubMed  PubMed Central  Google Scholar 

  • Ahmed MB et al (2022) cAMP signaling in cancer: a PKA-CREB and EPAC-centric approach. Cells 11(13):2020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bai Q et al (2022) Metastatic tumor cell-specific FABP7 promotes NSCLC metastasis via inhibiting beta-catenin degradation. Cells 11(5):805

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barzaman K et al (2020) Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol 84:106535

    Article  CAS  PubMed  Google Scholar 

  • Benatzy Y, Palmer MA, Brune B (2022) Arachidonate 15-lipoxygenase type B: regulation, function, and its role in pathophysiology. Front Pharmacol 13:1042420

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chang NW et al (2013) High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation. J Nutr Biochem 24(1):274–281

    Article  CAS  PubMed  Google Scholar 

  • Chang J et al (2023) Constructing a novel mitochondrial-related gene signature for evaluating the tumor immune microenvironment and predicting survival in stomach adenocarcinoma. J Transl Med 21(1):191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Charoentong P et al (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18(1):248–262

    Article  CAS  PubMed  Google Scholar 

  • Dalva M et al (2017) Copy number variants and VNTR length polymorphisms of the carboxyl-ester lipase (CEL) gene as risk factors in pancreatic cancer. Pancreatology 17(1):83–88

    Article  CAS  PubMed  Google Scholar 

  • Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Desai P, Aggarwal A (2021) Breast cancer in women over 65 years- a review of screening and treatment options. Clin Geriatr Med 37(4):611–623

    Article  PubMed  Google Scholar 

  • Dong H et al (2015) Inhibition of breast cancer cell migration by activation of cAMP signaling. Breast Cancer Res Treat 152(1):17–28

    Article  CAS  PubMed  Google Scholar 

  • Du B et al (2021) PAICS is related to glioma grade and can promote glioma growth and migration. J Cell Mol Med 25(16):7720–7733

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garufi C et al (2001) Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 12(2):179–182

    Article  CAS  PubMed  Google Scholar 

  • Giaquinto AN et al (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72(6):524–541

    Article  PubMed  Google Scholar 

  • Gombos A, Awada A (2017) Advances in chemical pharmacotherapy to manage advanced breast cancer. Expert Opin Pharmacother 18(1):95–103

    Article  CAS  PubMed  Google Scholar 

  • Grasso D et al (2020) Mitochondria in cancer. Cell Stress 4(6):114–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Harbeck N, Gnant M (2017) Breast cancer. Lancet 389(10074):1134–1150

    Article  PubMed  Google Scholar 

  • Huang J et al (2021) MTHFD2 facilitates breast cancer cell proliferation via the AKT signaling pathway. Exp Ther Med 22(1):703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ihle CL, Wright-Hobart SJ, Owens P (2022) Therapeutics targeting the metastatic breast cancer bone microenvironment. Pharmacol Ther 239:108280

    Article  CAS  PubMed  Google Scholar 

  • Jeong D et al (2021) ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer. Am J Cancer Res 11(6):2568–2589

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jeschke J et al (2017) DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. J Clin Invest 127(8):3090–3102

    Article  PubMed  PubMed Central  Google Scholar 

  • Jiang P et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550–1558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Johansson BB et al (2018) The role of the carboxyl ester lipase (CEL) gene in pancreatic disease. Pancreatology 18(1):12–19

    Article  CAS  PubMed  Google Scholar 

  • Kagawa Y et al (2019) Role of FABP7 in tumor cell signaling. Adv Biol Regul 71:206–218

    Article  CAS  PubMed  Google Scholar 

  • Kawiak A (2022) Molecular research and treatment of breast cancer. Int J Mol Sci 23(17):9617

    Article  PubMed  PubMed Central  Google Scholar 

  • Kciuk M, Marciniak B, Kontek R (2020) Irinotecan-still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci 21(14):4919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kittler R et al (2013) A comprehensive nuclear receptor network for breast cancer cells. Cell Rep 3(2):538–551

    Article  CAS  PubMed  Google Scholar 

  • Kopinski PK et al (2021) Mitochondrial DNA variation and cancer. Nat Rev Cancer 21(7):431–445

    Article  CAS  PubMed  Google Scholar 

  • Kulkarni S et al (2008) COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer 8:36

    Article  PubMed  PubMed Central  Google Scholar 

  • Lapatinib, in LiverTox: clinical and research information on drug-induced liver injury (2012) Bethesda (MD)

  • Le L et al (2023) 5-Azacytidine promotes HCC cell metastasis by up-regulating RDH16 expression. Eur J Pharmacol 950:175736

    Article  CAS  PubMed  Google Scholar 

  • Lin CH et al (2021) High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. NPJ Breast Cancer 7(1):88

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu ZH et al (2020) ZIC2 is downregulated and represses tumor growth via the regulation of STAT3 in breast cancer. Int J Cancer 147(2):505–518

    Article  CAS  PubMed  Google Scholar 

  • Liu X et al (2021a) PRRC2A promotes hepatocellular carcinoma progression and associates with immune infiltration. J Hepatocell Carcinoma 8:1495–1511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu H et al (2021b) Metabolic molecule PLA2G2D is a potential prognostic biomarker correlating with immune cell infiltration and the expression of immune checkpoint genes in cervical squamous cell carcinoma. Front Oncol 11:755668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lu J, Tan M, Cai Q (2015) The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 356(2 Pt A):156–64

    Article  CAS  PubMed  Google Scholar 

  • Mao YS et al (2020) Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database. Zhonghua Zhong Liu Za Zhi 42(3):228–233

    CAS  PubMed  Google Scholar 

  • Meng M et al (2018) Knockdown of PAICS inhibits malignant proliferation of human breast cancer cell lines. Biol Res 51(1):24

    Article  PubMed  PubMed Central  Google Scholar 

  • Meng C, Sun Y, Liu G (2023) Establishment of a prognostic model for ovarian cancer based on mitochondrial metabolism-related genes. Front Oncol 13:1144430

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Merino Bonilla JA, Torres Tabanera M, Ros Mendoza LH (2017) Breast cancer in the 21st century: from early detection to new therapies. Radiologia 59(5):368–379

    Article  CAS  PubMed  Google Scholar 

  • Niu M et al (2021) DCTPP1, an oncogene regulated by miR-378a-3p, promotes proliferation of breast cancer via DNA repair signaling pathway. Front Oncol 11:641931

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Oh DY, Bang YJ (2020) HER2-targeted therapies—a role beyond breast cancer. Nat Rev Clin Oncol 17(1):33–48

    Article  CAS  PubMed  Google Scholar 

  • Patergnani S et al (2020) Various aspects of calcium signaling in the regulation of apoptosis, autophagy, cell proliferation, and cancer. Int J Mol Sci 21(21):8323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361(9376):2235–2242

    Article  CAS  PubMed  Google Scholar 

  • Qiu P et al (2021) Characterization of exosome-related gene risk model to evaluate the tumor immune microenvironment and predict prognosis in triple-negative breast cancer. Front Immunol 12:736030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rickard BP et al (2023) Methods to evaluate changes in mitochondrial structure and function in cancer. Cancers (Basel) 15(9):2564

    Article  CAS  PubMed  Google Scholar 

  • Sainero-Alcolado L et al (2022) Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ 29(7):1304–1317

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saltz LB (1998) Irinotecan in the first-line treatment of colorectal cancer. Oncology (Williston Park) 12(8 Suppl 6):54–58

    CAS  PubMed  Google Scholar 

  • Seetharam R, Sood A, Goel S (2009) Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance. Ecancermedicalscience 3:153

    PubMed  PubMed Central  Google Scholar 

  • Shen DW et al (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64(3):706–721

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Siegel RL et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48

    Article  PubMed  Google Scholar 

  • Sun Z et al (2022a) FABP7 inhibits proliferation and invasion abilities of cutaneous squamous cell carcinoma cells via the Notch signaling pathway. Oncol Lett 24(2):254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sun L et al (2022b) Lapatinib induces mitochondrial dysfunction to enhance oxidative stress and ferroptosis in doxorubicin-induced cardiomyocytes via inhibition of PI3K/AKT signaling pathway. Bioengineered 13(1):48–60

    Article  CAS  PubMed  Google Scholar 

  • Suo J et al (2021) A retrospective analysis of the effect of irinotecan-based regimens in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Front Oncol 11:654974

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Thomas R et al (2019) ACSL1 regulates TNFalpha-induced GM-CSF production by breast cancer MDA-MB-231 Cells. Biomolecules 9(10):555

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Trapani D et al (2022) Global challenges and policy solutions in breast cancer control. Cancer Treat Rev 104:102339

    Article  PubMed  Google Scholar 

  • Vasan K, Werner M, Chandel NS (2020) Mitochondrial metabolism as a target for cancer therapy. Cell Metab 32(3):341–352

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang S et al (2021) Nilotinib, a discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer. Neoplasma 68(5):975–982

    Article  CAS  PubMed  Google Scholar 

  • Wang Y et al (2022a) Mitochondrial-related transcriptome feature correlates with prognosis, vascular invasion, tumor microenvironment, and treatment response in hepatocellular carcinoma. Oxid Med Cell Longev 2022:1592905

    PubMed  PubMed Central  Google Scholar 

  • Wang Y et al (2022b) ROS-induced DCTPP1 upregulation contributes to cisplatin resistance in ovarian cancer. Front Mol Biosci 9:838006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Winters S et al (2017) Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci 151:1–32

    Article  CAS  PubMed  Google Scholar 

  • Wu J et al (2021) A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Oncogene 40(26):4413–4424

    Article  CAS  PubMed  Google Scholar 

  • Xia LL et al (2016) DCTPP1 attenuates the sensitivity of human gastric cancer cells to 5-fluorouracil by up-regulating MDR1 expression epigenetically. Oncotarget 7(42):68623–68637

    Article  PubMed  PubMed Central  Google Scholar 

  • Yang Y et al (2016) Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. J Cell Physiol 231(12):2570–2581

    Article  CAS  PubMed  Google Scholar 

  • Zhang J et al (2020) Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target. Theranostics 10(18):8315–8342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang H et al (2023a) Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer. Front Oncol 13:1098357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang Q et al (2023b) ACSL1-induced ferroptosis and platinum resistance in ovarian cancer by increasing FSP1 N-myristylation and stability. Cell Death Discov 9(1):83

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhao B et al (2022) The role of PPARs in breast cancer. Cells 12(1):130

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was sponsored by Quanzhou City Science & Technology Program of China (2019N086S).

Author information

Author notes

  1. Yuting Lin and Zhongxin Huang have equally contributed to this work.

Authors and Affiliations

  1. Traditional Chinese Medicine Department, The Second Affiliated Hospital of Fujian Medical University, No. 34, North Zhongshan Road, Quanzhou, 362000, China

    Yuting Lin, Baogen Zhang, Hanhui Yang & Shu Yang

  2. Pathology Department, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China

    Zhongxin Huang

Authors
  1. Yuting Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhongxin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baogen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hanhui Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: ZH and YL. Data curation: HY and BZ. Formal analysis: HY and SY. Funding acquisition: SY. Writing of the manuscript: ZH and YL. Supervision: YL and BZ.

Corresponding author

Correspondence to Shu Yang.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Ethical Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

All authors consent to submit the manuscript for publication.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, Y., Huang, Z., Zhang, B. et al. Construction and Analysis of a Mitochondrial Metabolism-Related Prognostic Model for Breast Cancer to Evaluate Survival and Immunotherapy. J Membrane Biol 257, 63–78 (2024). https://doi.org/10.1007/s00232-024-00308-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00232-024-00308-1

Keywords

Search

Navigation